Extended Data Figure 1. gp130^Act expression and intestinal phenotype.

(a) Schematic diagram of the villin-gp130^Act transgenic (Tg) construct and the gp130^Act and gp130^SA variants. (b) Expression of gp130^Act in the villin-gp130^Act jejunum was confirmed by RT-PCR with specific primers for human gp130. Cyclophilin (CPH) was used as an internal control. (c) Representative images of WT and villin-gp130^Act intestines. c-Myc and CyclinD1 (d) and TUNEL (red: TUNEL; blue: DAPI) (e) staining of paraffin-embedded sections of WT and villin-gp130^Act small intestines from 3-month old mice. Positive cells were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (f) MMP7, AB and ChrA positive cells in WT and villin-gp130^Act small intestines were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (g) Paraffin embedded sections of WT and villin-gp130^Act small intestines were analyzed by PAS and lysozyme staining. Positive cells were enumerated in each villus or crypt (n=6). Data represent averages ± SD. *P < 0.05. (h) Cryptdin mRNA in WT and villin-gp130^Act jejunum was detected by in situ hybridization. (i) Transmission electron microscopy (TEM) of the apical surface of WT and Tg small intestines. Scale bars represent 100 μm (d, e, g, h) and 1 μm (i) and all data are representative of at least 2–3 independent experiments.